MSTN and obesity disorder: Although, both anabolic and catabolic pathways are well described, i.e., AKT inhibits FoxO and myostatin-SMAD 2/3 inhibits AKT [3], the exact regulation of protein metabolism during obesity is still incompletely characterized [7].